Stock Analiz

Metagenomi Therapeutics, Inc. MGX

Biotechnology: Biological Products (No Diagnostic Substances) · IPO 2024 · data as of November 13, 2026

$0.69Market cap $26M
Open the interactive analysis →

Metagenomi Therapeutics, Inc. (MGX) is a healthcare company listed in the US with a market value of about $26M. In the twelve months to September 30, 2026 it had revenue of $7M and net income of -$94M, a net margin of -1329.3%.

Its overall Stock Analiz score is 0.6 out of 5 (weak). The strongest part is financial health (2/5); the weakest is value (0/5).

Key numbers: a 5-year average ROIC of -39%.

About Metagenomi Therapeutics

Metagenomi Therapeutics is listed in the US and classified in biotechnology: biological products (no diagnostic substances), IPO year 2024. It was profitable in 0 of the last 3 years in our data. It spends 375% of revenue on research and development.

Score: 0.6 / 5

Value0/5
Future growth1/5
Track record0/5
Financial health2/5
Shareholder returns0/5

Checks passed

  • Strong R&D investment or growth above 20%
  • More cash than debt, or low debt to equity
  • Liabilities below 60% of assets

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • Profit margin improving

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S3.7
P/B0.3
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield-319.4%
Shareholder yield0.0%
Intrinsic value vs. price—

Growth and quality

Revenue growth (1 yr)-51.8%
Revenue growth (5 yrs, per year)—
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-216.8%
ROIC (5-yr avg.)-38.9%
Profitable years (of last 10)0
Years paying a dividend—

Financials, last 3 years

Fiscal yearTTM202520242023
Revenue$7M$25M$52M$45M
Net income-$94M-$88M-$78M-$68M
Free cash flow-$84M-$89M-$112M-$101M
EPS (diluted)$-2.50$-2.36$-2.36$-20.05
Net margin-1329.3%-348.5%-149.3%-152.5%
ROIC—-48.1%-29.6%—

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

Frequently asked questions

Does Metagenomi Therapeutics pay a dividend?

Not currently.

Is Metagenomi Therapeutics a good stock to buy?

We do not give buy or sell advice. Metagenomi Therapeutics scores 0.6 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.